Table 3.

Systemic immune-inflammatory index at univariate analysis

	All sample (n = 1,169)	Lung (n = 635)	RCC (n = 200)	Melanoma (n = 150)
	HR (95% CI); p value	HR (95% CI); p value	HR (95% CI); p value	HR (95% CI); p value
SII (continuous; 1,000-unit difference)	1.06 (1.03–1.08); p < 0.001, c-index = 0.592	1.05 (1.02–1.08); p = 0.002, c-index = 0.568	1.18 (1.01–1.37); p = 0.034, c-index = 0.603	1.22 (1.01–1.47); p = 0.038, c-index = 0.589
SII
<831	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
≥831	1.71 (1.43–2.05); p < 0.001, c-index = 0.570	1.41 (1.13–1.78); p = 0.003, c-index = 0.547	1.81 (1.13–2.91); p = 0.014, c-index = 0.576	2.05 (1.13–3.74); p = 0.019, c-index = 0.595
SII
<1,444	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
≥1,444	1.67 (1.39–2.02); p < 0.001, c-index = 0.557	1.43 (1.13–1.81); p = 0.003, c-index = 0.545	1.92 (1.14–3.24); p = 0.014, c-index = 0.556	2.23 (1.12–4.42); p = 0.022, c-index = 0.569

95% CI, 95% confidence interval; HR, hazard ratio; n, number; RCC, renal cell carcinoma; SII, systemic immune-inflammatory index.